Insights from human studies into the host defense against candidiasis

Cytokine

Volumn 58, Issue 1, 2012, Pages 129-132

  Filler, Scott G ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Candida; CARD9; Dectin 1; Host defense; Th17

Indexed keywords

AUTOANTIBODY; CARD9 PROTEIN; CASPASE RECRUITMENT DOMAIN 9 PROTEIN; DECTIN 1; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 22; PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

AIRE GENE; ARTICLE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CANDIDIASIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; FUNGAL COLONIZATION; GASTROINTESTINAL CANDIDIASIS; GENE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HOST RESISTANCE; HUMAN; HYPER IGE SYNDROME; INFECTION SENSITIVITY; INTERLEUKIN 17A RECEPTOR GENE; INTERLEUKIN 17F GENE; INVASIVE CANDIDIASIS; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; STOP CODON; TH17 CELL; VAGINA CANDIDIASIS;

ANIMALS; CANDIDIASIS; CANDIDIASIS, CHRONIC MUCOCUTANEOUS; CANDIDIASIS, VULVOVAGINAL; CARD SIGNALING ADAPTOR PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LECTINS, C-TYPE; MICE; TH17 CELLS;

CANDIDA; MUS;

EID: 84857449203     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.09.018     Document Type: Article

References (29)

1. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
2. Drummond R.A., Brown G.D. The role of dectin-1 in the host defence against fungal infections. Curr Opin Microbiol 2011, 14:392-399.
3. Lee H.M., Yuk J.M., Shin D.M., Jo E.K. Dectin-1 is inducible and plays an essential role for mycobacteria-induced innate immune responses in airway epithelial cells. J Clin Immunol 2009, 29:795-805.
4. Taylor P.R., Tsoni S.V., Willment J.A., Dennehy K.M., Rosas M., Findon H., et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 2007, 8:31-38.
5. Saijo S., Fujikado N., Furuta T., Chung S.H., Kotaki H., Seki K., et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 2007, 8:39-46.
6. Gales A., Conduche A., Bernad J., Lefevre L., Olagnier D., Beraud M., et al. PPARgamma controls dectin-1 expression required for host antifungal defense against Candida albicans. PLoS Pathog 2010, 6:e1000714.
7. Ferwerda B., Ferwerda G., Plantinga T.S., Willment J.A., van Spriel A.B., Venselaar H., et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009, 361:1760-1767.
8. Plantinga T.S., van der Velden W.J., Ferwerda B., van Spriel A.B., Adema G., Feuth T., et al. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis 2009, 49:724-732.
9. Rosentul D.C., Plantinga T.S., Oosting M., Scott W.K., Velez Edwards D.R., Smith P.B., et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis 2011, 204:1138-1145.
10. Plantinga T.S., Hamza O.J., Willment J.A., Ferwerda B., van de Geer N.M., Verweij P.E., et al. Genetic variation of innate immune genes in HIV-infected African patients with or without oropharyngeal candidiasis. J Acquir Immune Defic Syndr 2010, 55:87-94.
11. Gross O., Gewies A., Finger K., Schafer M., Sparwasser T., Peschel C., et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006, 442:651-656.
12. Glocker E.O., Hennigs A., Nabavi M., Schaffer A.A., Woellner C., Salzer U., et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009, 361:1727-1735.
13. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
14. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
15. Gaffen S.L., Hernandez-Santos N., Peterson A.C. IL-17 signaling in host defense against Candida albicans. Immunol Res 2011, 50:181-187.
16. Huang W., Na L., Fidel P.L., Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004, 190:624-631.
17. De Luca A., Zelante T., D'Angelo C., Zagarella S., Fallarino F., Spreca A., et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol 2010, 3:361-373.
18. Conti H.R., Shen F., Nayyar N., Stocum E., Sun J.N., Lindemann M.J., et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009, 206:299-311.
19. Kagami S., Rizzo H.L., Kurtz S.E., Miller L.S., Blauvelt A. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 2010, 185:5453-5462.
20. Zelante T., De Luca A., Bonifazi P., Montagnoli C., Bozza S., Moretti S., et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007, 37:2695-2706.
21. Holland S.M., DeLeo F.R., Elloumi H.Z., Hsu A.P., Uzel G., Brodsky N., et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007, 357:1608-1619.
22. Minegishi Y., Saito M., Tsuchiya S., Tsuge I., Takada H., Hara T., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058-1062.
23. Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
24. Conti H.R., Baker O., Freeman A.F., Jang W.S., Holland S.M., Li R.A., et al. New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome. Mucosal Immunol 2011, 4:448-455.
25. Liu L., Okada S., Kong X.F., Kreins A.Y., Cypowyj S., Abhyankar A., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011, 208:1635-1648.
26. van de Veerdonk F.L., Plantinga T.S., Hoischen A., Smeekens S.P., Joosten L.A., Gilissen C., et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011, 365:54-61.
27. Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332:65-68.
28. Kisand K., Boe Wolff A.S., Podkrajsek K.T., Tserel L., Link M., Kisand K.V., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010, 207:299-308.
29. Puel A., Doffinger R., Natividad A., Chrabieh M., Barcenas-Morales G., Picard C., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010, 207:291-297.